Drug intelligence / Profile preview

ICT6098

Development stage: Unknown
Lead developer: Innovative Cellular Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

ICT6098 is an autologous CAR-T cell therapy developed by Innovative Cellular Therapeutics (ICT) for the treatment of pancreatic cancer. It utilizes the company's proprietary CoupledCAR and InvivoCAR platforms, which are engineered to enhance the expansion, persistence, and efficacy of T cells within the challenging immunosuppressive microenvironment of solid tumors. While the specific molecular target of ICT6098 is currently undisclosed, the candidate is part of a pipeline of next-generation cellular therapies aimed at addressing unmet needs in oncology. An Investigational New Drug (IND) submission for ICT6098 is anticipated in the second half of 2027.

Targets

MAGEA8 (Melanoma-associated antigen 8)

Beyond the preview

Go deeper on ICT6098.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ICT6098.

Explore the full profile